鶹ý

New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results

— News, features, and commentary about cancer-related issues

MedpageToday
Onco Break over a computer rendering of a cancer cell.

Two-thirds of approved by the European Medicines Agency from 1995 to 2020 had little or no supporting evidence of added clinical benefit, particularly drugs that had fast-track designation. (The BMJ)

Meanwhile, the launched in 2023 was 35% higher as compared with drugs first marketed in 2022. (Reuters)

Actinium Pharmaceuticals announced that its targeted radiotherapy product I-131 apamistamab (Iomab-B) significantly improved long-term survival in older patients with relapsed/refractory .

The glitazone class of diabetes drugs may have the added benefit of . (University of Bristol, BMJ Open)

A large retrospective cohort study showed that Black and Hispanic patients had after neoadjuvant therapy and surgery, likely involving multiple factors. (Fox Chase Cancer Center, JAMA Network Open)

A new survey showed that a majority of Americans didn't know that alcohol use is associated with . (The Ohio State University Comprehensive Cancer Center)

may reduce the effectiveness of chemotherapy for head and neck cancer. (OU Health Sciences)

with higher levels of stromal (normal) tissue were more likely to develop resistance to chemotherapy. (University of Minnesota, JAMA Network Open)

Medical device maker iCAD announced that its artificial intelligence-supported reduced radiologists' workload and the recall rate with no increase in false-negative results.

Young women with newly diagnosed breast cancer may have to make split-second decisions about . (New York Times)

  • author['full_name']

    Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 鶹ý in 2007.